This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

Condition	Treatment or Intervention	Phase
Secondary Hyperparathyroidism End Stage Renal Disease	Drug: AMG 073	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Patients must be receiving hemodialysis;
• Have elevated parathyroid hormone levels;
• Not be pregnant or nursing; and
• Not have had a heart attack in the last 3 months.

Alabama
      Research Site, Birmingham,  Alabama,  United States
California
      Research Center, Walnut Creek,  California,  United States
      Research Center, San Diego,  California,  United States
Colorado
      Research Center, Denver,  Colorado,  United States
      Research Center, Thornton,  Colorado,  United States
Florida
      Research Center, Miami,  Florida,  United States
Illinois
      Research Site, Chicago,  Illinois,  United States
Iowa
      Research Center, Des Moines,  Iowa,  United States
Maryland
      Research Center, Rockville,  Maryland,  United States
Massachusetts
      Research Center, Boston,  Massachusetts,  United States
Missouri
      Research Center, St. Louis,  Missouri,  United States
Nevada
      Research Center, Las Vegas,  Nevada,  United States
New York
      Research Center, Rochester,  New York,  United States
North Carolina
      Research Center, Chapel Hill,  North Carolina,  United States
      Research Center, Asheville,  North Carolina,  United States
Ohio
      Research Center, Norwood,  Ohio,  United States
      Research Center, Cincinnati,  Ohio,  United States
Oregon
      Research Center, Portland,  Oregon,  United States
Pennsylvania
      Research Center, Philadelphia,  Pennsylvania,  United States
Tennessee
      Research Center, Nashville,  Tennessee,  United States

Study ID Numbers:  20000172
Record last reviewed:  January 2003
Last Updated:  October 13, 2004
Record first received:  May 17, 2002
ClinicalTrials.gov Identifier:  NCT00037635
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08